Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety.
Liao Z, Li F, Zhang C, Zhu L, Shi Y, Zhao G, Bai X, Hassan S, Liu X, Li T, Xing P, Zhao J, Zhang J, Xing R, Teng S, Yang Y, Chen K, Yang J.
Liao Z, et al. Among authors: teng s.
Exp Mol Med. 2019 Feb 28;51(3):1-11. doi: 10.1038/s12276-019-0221-7.
Exp Mol Med. 2019.
PMID: 30816108
Free PMC article.
Clinical Trial.